New Geneseeq Pancreas Blood Test Brings Early Diagnosis Closer | Free generative fill ai | Microsoft ai copilot | Generative ai tools free | Turtles AI

Geneseeq Technology Inc., in collaboration with international clinical institutions, has developed a novel blood test for the early detection of pancreatic cancer. Using circulating cell-free DNA (cfDNA) fragmentation analysis and AI algorithms, the test demonstrated high accuracy in detecting early-stage pancreatic ductal carcinoma (PDAC). Published in the Journal of Clinical Oncology, the study highlights the test’s potential utility in early screening and monitoring high-risk patients.

Key Points:

• Sensitivity of 95.8% and specificity of 95.2% in the training cohort.
• High accuracy even in early-stage tumors.
• Superior to CA19-9, especially in patients with normal bilirubin levels.
• Potential to reduce pancreatic cancer mortality by up to 27%.

Pancreatic ductal carcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate of less than 12%, mainly due to late diagnosis. Currently, there are no recommended screening methods for the entire population. The new test developed by Geneseeq analyzes specific patterns of cfDNA fragmentation, which are DNA fragments released into the bloodstream by tumor cells. By applying advanced machine learning algorithms to low-coverage whole-genome sequencing data (as low as 0.5x), the test can detect subtle genomic and epigenetic changes associated with early PDAC.

In a prospective study involving 647 participants, the model showed an area under the curve (AUC) of 0.993 in the training cohort and 0.990 in the validation cohort. Sensitivity was 95.8% and specificity 95.2% in the training cohort, while sensitivity reached 99.1% with a specificity of 91.0% in the validation cohort. The test performed well even in early-stage cancers and outperformed the CA19-9 test, especially in individuals with normal bilirubin levels.

The clinical feasibility of the test is supported by its high stability, even with lower DNA sequencing data, making it cost-effective and suitable for larger population screening. Researchers estimate that population-wide application of this test could reduce pancreatic cancer mortality by up to 27% by detecting more cancers at a treatable stage.

Further research is underway to refine the model’s application in screening programs and validate its effectiveness in more diverse populations. Clinicians may soon have a powerful new tool to combat one of the most difficult cancers to detect.

Geneseeq Technology Inc. is a leader in precision oncology research, using next-generation sequencing technologies to advance cancer care. The company provides comprehensive genomic profiling solutions for all tumor types and has achieved key regulatory milestones, including CE-IVD certification for its solid tumor and hematologic tumor panels, as well as FDA Breakthrough Device designation for its MCED test, CanScan®.

With the advancement of sequencing technologies and the integration of AI, the landscape of early pancreatic cancer diagnosis could see significant improvements, offering new hope for patients.